{
  "id": 14618291,
  "title": "PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis",
  "url": "https://urgent.news/2026/10/15/pedra-2026-nemolizumab-phase-ii-data-show-long-term-symptom-relief",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-15T05:04:25.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/pedra-2026-nemolizumab-phase-ii-data-show-long-term-symptom-relief-for-children-aged-2-to-11-years-with-moderate-to-severe-atopic-dermatitis"
  },
  "original_language": "en",
  "account": null,
  "summary": "Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}